Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTMCPZ)

Drug Name
KB001A Drug Info
Indication
Disease Entry ICD 11 Status REF
Cystic fibrosis CA25 Phase 2 [1]
Infectious disease 1A00-CA43.1 Phase 2 [2]
Cross-matching ID
TTD Drug ID
DMTMCPZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Pseudomonas PcrV protein type III (Pseudo pcrV)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MEDI3902 DMOXKIC Ventilator-associated pneumonia PK81.0 Phase 2 [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Pseudomonas PcrV protein type III (Pseudo pcrV) TTLK9NJ O30527_PSEAI Inhibitor [3]

References

1 ClinicalTrials.gov (NCT00638365) Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT01695343) Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment. U.S. National Institutes of Health.
3 KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. J Cyst Fibros. 2018 Jul;17(4):484-491.
4 A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med. 2014 Nov 12;6(262):262ra155.